Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-acting inhaled beta 2-agonists for stable COPD.

John A Dougherty1, Bethany L Didur, Loutfi S Aboussouan

  • 1Clinical Services, Pharmacy Department, Florida Hospital, Orlando, FL 32803-1248, USA. john.dougherty@flhosp.org

The Annals of Pharmacotherapy
|August 19, 2003
PubMed
Summary

Long-acting beta(2)-agonists offer convenient dosing and improve symptoms for chronic obstructive pulmonary disease (COPD) patients. These bronchodilators are considered acceptable first-line treatments for COPD management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real world challenges: effectiveness of automatically adjusted noninvasive ventilation in obesity hypoventilation syndrome.

American journal of respiratory and critical care medicine·2026
Same author

Challenges in the Early Diagnosis, Screening and Management of Heart Failure in Patients with Chronic Obstructive Pulmonary Disease.

Journal of clinical medicine·2026
Same author

Multidisciplinary Evaluation for COPD Management.

Respiratory care·2025
Same author

Goals of chronic obstructive pulmonary disease management: a focused review for clinicians.

Current opinion in pulmonary medicine·2024
Same author

The Interconnectedness of Interprofessional Education and Professional Identity Formation.

American journal of pharmaceutical education·2024
Same author

A systematic review of cost-effectiveness analyses of gene therapy for hemophilia type A and B.

Journal of managed care & specialty pharmacy·2024

Area of Science:

  • Pulmonary Medicine
  • Pharmacology

Background:

  • Chronic obstructive pulmonary disease (COPD) incidence and mortality have risen globally.
  • COPD is a progressive, irreversible condition marked by chronic cough, dyspnea, and wheezing.
  • No medication, except oxygen, has proven to decrease COPD mortality.

Purpose of the Study:

  • To review the pathogenesis of COPD.
  • To examine the benefits, formulations, costs, pharmacokinetics, and clinical studies of long-acting beta(2)-agonists (LABAs).

Main Methods:

  • A comprehensive MEDLINE search was conducted from July 1966 to October 2002.
  • Articles focusing on COPD and long-acting beta(2)-agonists were selected for review.

Main Results:

  • Long-acting beta(2)-agonists (formoterol, salmeterol) offer twice-daily dosing convenience over short-acting bronchodilators.

Related Experiment Videos

  • Both formoterol and salmeterol demonstrate acceptable safety profiles at recommended doses.
  • LABAs have shown benefits in improving COPD symptoms, spirometry, exacerbations, and quality of life compared to ipratropium and theophylline.

    • Conclusions:

    • Long-acting beta(2)-agonists are recommended as acceptable first-line agents for COPD management.
    • Further clinical outcome studies directly comparing formoterol and salmeterol are warranted.